CHRONOBIOLOGIC CARDIOVASCULAR TRACKING FROM BIRTH

评估昼夜节律发育和先天性 心血管疾病风险、血压（BP）、心率（HR）和 唾液醛固酮将在出生后48小时内进行监测， 330个新生儿。 出生后48小时，循环醛固酮， 将测定TSH和DHEA-S以及超声心动图。 父母 &其他可访问的家庭成员将贡献48小时BP & HR配置文件与完全动态血压监测器或使用 专门设计的最小抽样方案， 干扰日常活动，但允许评估BP和HR 动力学，一个房间限制显示器。 一份问卷将 特别询问高血压和糖尿病家族史。 所有 将对婴儿进行单独跟踪， 1.5-每隔一年提供4个配置文件（210名婴儿）， 相当于或类似于0.5年和相当于或类似于4.5年 年龄，48小时血压，心率和唾液醛固酮谱，血液 醛固酮，促甲状腺激素和脱氢表雄酮-S和超声心动图。 时间生物学分析将1）为以下方面提供参考标准： 趋势调整均值和动态心血管特征，包括 一个时间生物学指数来识别，在出生时， 在以后的生活中发展高血压; 2）量化年龄趋势; 3）显示 不同（生理或成像）心血管疾病之间的关系 和内分泌变量; 4）表明成本效益的新生儿 出生时随访BP和HR均值和动态的预测因子 特征; 5）通过BP跟踪的标准， 回忆或定量（家族）的相对优点 基于测量的）家族史，时间生物学和 家庭BP和HP监测的常规终点以及 心血管疾病风险的新生儿时间生物学预测因子。 聚类分析应该回答一个问题， 新生儿指数分类风险比最好的定量 家族史或血压记录 如果是这样，新生儿指数将衡量 干预对孕妇及孕妇基础的影响 对新生儿进行个体化饮食干预的适应症。

To assess circadian rhythm development & congenital cardiovascular disease risk, blood pressure (BP), heart rate (HR) & salivary aldosterone will be monitored for 48 hours after birth on 330 newborns. At 48 hours after birth, circulating aldosterone, TSH &DHEA-S & an echocardiogram will be determined. Parents & other accessible family members will contribute a 48-hours BP & HR profile with a fully ambulatory BP monitor or using specially-designed minimal sampling schemes that do not interfere with daily activities yet allow assessment of BP & HR dynamics, with a room-restricted monitor. A questionnaire will inquire notably about a family history of high BP & diabetes. All infants will be individually tracked, at equivalent or similar to 1.5-year intervals to provide up to 4 profiles (210 infants) between equivalent or similar to 0.5 and equivalent or similar to 4.5 years of age, for a 48-h BP, HR & salivary aldosterone profile, a blood aldosterone, TSH & DHEA-S & an echocardiogram. Chronobiologic analyses will 1) provide reference standards for trend-adjusted means & dynamic cardiovascular features including a chronobiologic index to recognize, at birth, the risk of developing a high BP later in life; 2) quantify age trends; 3) show relations among different (physiologic or imaging) cardiovascular & endocrine variables; 4) indicate the cost-effective neonatal predictor at birth of the follow-up BP & HR means & dynamic characteristics; & 5) compare, by the criterion of BP tracking, the relative merits of an anamnestic or quantitative (familial measurement-based) family history, the chronobiologic & conventional endpoints from familial BP & HP monitoring & the neonatal chronobiologic predictors of cardiovascular disease risk. Cluster analysis should answer the question whether a dynamic neonatal index classifies risk better than the best quantitative family history or BP profile. If so, a neonatal index would gauge the effect of intervention on the pregnant woman & underlie indications for individualized dietary intervention on the newborn.